Transdermal Therapeutic System for 5-Aminolevulinic Acid Hydrochloride
AssigneesLTS Lohmann Therapie-Systeme AG, Photonamic GmbH & Co. KG
InventorsTobias JUNG, Michael HORSTMANN, Gerd HOFFMANN
Life of this patent
Estimating the term…
Abstract
The invention relates to a transdermal therapeutic system that includes a back layer that is impermeable to an active ingredient; a polymer matrix containing the active ingredient and a protective layer that can be pulled off. The active ingredient is 5-aminolevulinic acid hydrochloride and the basic polymer of the polymer matrix is an adhesive polyacrylate. The inventive transdermal therapeutic systems are suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.
Claims25
A transdermal therapeutic system comprising a back layer that is impermeable to an active ingredient, an active ingredient-containing polymer matrix and a protective layer that can be pulled off,
- wherein the transdermal therapeutic system is a monolithic active ingredient-in-adhesive system;
- the active ingredient is 5-aminolevulinic acid hydrochloride, which is present in an amount of 10 to 30% by weight based on the polymer matrix;
- the polymer matrix contains more than 60% by weight of an adhesive polyacrylate having a viscosity of 500 to 25,000 mPa-s at 25° C.;
- the adhesive polyacrylate is based on acrylic acid, butyl acrylate, 2-ethylhexyl acrylate and vinyl acetate or based on acrylic acid, 2-ethylhexyl acrylate and methyl acrylate, and
- the adhesive polyacrylate does not comprise a cross-linking agent.
A method for treating skin cancer, said method comprising:
- adhering a transdermal therapeutic system containing 5-aminolevulinic acid hydrochloride in the form of particles less than 250 μm to skin at a place affected by cancer or precancerous lesions,
- allowing said 5-aminolevulinic acid hydrochloride to dissolve via sweat from the place on the skin where the transdermal therapeutic system is applied,
- transdermally absorbing the dissolved 5-aminolevulinic acid hydrochloride and enriching the concentration of 5-aminolevulinic acid hydrochloride in proximity of said cancer or precancerous lesions,
- allowing said 5-aminolevulinic acid hydrochloride to convert into protoporphyrin IX,
- irradiating said cancer or precancerous lesions enriched with protoporphyrin IX with light of a wavelength selected from the group consisting of 408 nm, 506 nm, 532 nm, 580 nm and 635 nm, thereby producing reactive oxygen compounds, and
- allowing said reactive oxygen compounds to induce necrosis in said cancer or precancerous lesions.
Dependencies are inferred from the claim text.